Download E. erbB

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
page
9
Document related concepts
no text concepts found
Transcript 
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering
alterations erbB signaling pathway genes and p53 in lung cancer patients. P values were
calculated using logrank test.
A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value
of 3 or more per cell (all samples).
B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value
of 2.5 or more per cell (all samples).
C. RASSF1A methylated (M) versus unmethylated (U) (all samples).
D. EGFR mutated (M) versus wild type (WT) [all samples].
E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated,
RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples).
F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated,
RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma).
G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated,
RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell
carcinoma).
H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated,
RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no
alteration (squamous cell carcinoma).
A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients
with a value of 3 or more per cell (all samples).
P=0.64
Months
B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with
a value of 2.5 or more per cell (all samples).
P=0.38
Months
C. RASSF1A methylated (M) versus unmethylated (U) (all samples).
P=0.99
Months
D. EGFR mutated (M) versus wild type (WT) [all samples].
P=0.64
Months
E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras
mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all
samples).
P=0.63
Months
F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras
mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration
(adenocarcinoma)
P=0.74
Months
G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras
mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration
(squamous cell carcinoma).
P=0.93
Months
H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras
mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53))
versus no alteration (squamous cell carcinoma).
P=0.09
Months
Related documents